Nyowani Nherera Mushonga Dhizaini yeKurapwa kweFollicular Lymphoma

January 21, 2022
by mupepeti
Add Comment
2 min kuverenga
en English
af Afrikaanssq Albanianam Amharicar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbn Bengalibs Bosnianbg Bulgarianca Catalanceb Cebuanony Chichewazh-CN Chinese (Simplified)zh-TW Chinese (Traditional)co Corsicanhr Croatiancs Czechda Danishnl Dutchen Englisheo Esperantoet Estoniantl Filipinofi Finnishfr Frenchfy Frisiangl Galicianka Georgiande Germanel Greekgu Gujaratiht Haitian Creoleha Hausahaw Hawaiianiw Hebrewhi Hindihmn Hmonghu Hungarianis Icelandicig Igboid Indonesianga Irishit Italianja Japanesejw Javanesekn Kannadakk Kazakhkm Khmerko Koreanku Kurdish (Kurmanji)ky Kyrgyzlo Laola Latinlv Latvianlt Lithuanianlb Luxembourgishmk Macedonianmg Malagasyms Malayml Malayalammt Maltesemi Maorimr Marathimn Mongolianmy Myanmar (Burmese)ne Nepalino Norwegianps Pashtofa Persianpl Polishpt Portuguesepa Punjabiro Romanianru Russiansm Samoangd Scottish Gaelicsr Serbianst Sesothosn Shonasd Sindhisi Sinhalask Slovaksl Slovenianso Somalies Spanishsu Sudanesesw Swahilisv Swedishtg Tajikta Tamilte Teluguth Thaitr Turkishuk Ukrainianur Urduuz Uzbekvi Vietnamesecy Welshxh Xhosayi Yiddishyo Yorubazu Zulu
rakanyorwa mupepeti

CASI Pharmaceuticals, Inc., kambani yekuUS biopharmaceutical yakatarisana nekugadzira nekutengesa hunyanzvi hwekurapa uye zvigadzirwa zvemishonga, yakazivisa nhasi, kuti US Food and Drug Administration (FDA) yakapa Orphan Drug Disignation (ODD) kune mumwe wayo BioInvent International AB, kuti. BI-1206, an investigational anti-FcyRllB antibody, yekurapa follicular lymphoma (FL), iyo inowanzozivikanwa yeinononoka-kukura Non-Hodgkin lymphoma (NHL).

Print Friendly, PDF & Email

BI-1206 ndiyo inotungamira mushonga weBioInvent uye parizvino iri kuferefetwa mumaedzo maviri eChikamu 1/2. Imwe ndeyekuongorora BI-1206 musanganiswa ne rituximab pakurapwa kweNon-Hodgkin lymphoma, iyo inosanganisira varwere vane FL, MCL uye marginal zone lymphoma (MZL) vakadzokera shure kana kuti vari kuramba rituximab. Yechipiri Phase 1/2 muyedzo iri kuongorora BI-1206 musanganiswa ne-anti-PD1 therapy Keytruda® (pembrolizumab) mumamota akasimba.

Dr. Wei-Wu He, Sachigaro weCASI, uye CEO vakati, "BioInvent inoramba ichifambira mberi nekuvandudza uye kutonga kweBI-1206. Mvumo yeCTA muChina muna Zvita 2021 uye ichangoburwa FDA Orphan Drug Designation inoratidza kugona kwakasimba kweiyi yekutanga-mu-kirasi antibody. CASI ine kodzero dzekutengesa dzekuChina dzeBI-1026, uye timu yedu iri kugadzirira Chidzidzo chekiriniki yeChina. CASI neBioInvent vadyidzani vasina musono uye vane chinangwa chakafanana chekubatsira varwere vane tekinoroji yemishonga.

Print Friendly, PDF & Email

Ungazvidyawo kufanana

Nezvomunyori

mupepeti

Mupepeti mukuru we eTurboNew ndiLinda Hohnholz. Iye anogara muTN HQ muHonolulu, Hawaii.

Tarisa zvese zvawatumira

Leave a Comment

eTurboNews | eTN